RNAi Modulation of Placental sFLT1 for the Treatment of Preeclampsia.

[1]  S. Crooke,et al.  Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides , 2018, Nucleic acids research.

[2]  M. Moore,et al.  Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo , 2018, Nucleic acids research.

[3]  A. Khvorova,et al.  Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay. , 2017, Nucleic acid therapeutics.

[4]  Ling Feng,et al.  Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery. , 2017, Placenta.

[5]  J. Bailey,et al.  FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia , 2017, Scientific Reports.

[6]  K. G. Rajeev,et al.  Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates , 2017, Nucleic acids research.

[7]  B. Sibai,et al.  Short‐term costs of preeclampsia to the United States health care system , 2017, American journal of obstetrics and gynecology.

[8]  A. Akinc,et al.  Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy , 2017, The New England journal of medicine.

[9]  A. Khvorova,et al.  5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo , 2017, Nucleic acids research.

[10]  K. Koh.  A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. , 2017, The New England journal of medicine.

[11]  anastasia. khvorova,et al.  The chemical evolution of oligonucleotide therapies of clinical utility , 2017, Nature Biotechnology.

[12]  B. Bettencourt,et al.  A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 , 2017, The New England journal of medicine.

[13]  A. Khvorova.  Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. , 2017, The New England journal of medicine.

[14]  T. Henriksen,et al.  In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies. , 2016, American journal of obstetrics and gynecology.

[15]  Lawrence M. Lifshitz,et al.  Visualization of self-delivering hydrophobically modified siRNA cellular internalization , 2016, Nucleic acids research.

[16]  Johnf . Thompson,et al.  Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates , 2016, Hypertension.

[17]  S. Karumanchi.  Angiogenic Factors in Preeclampsia: From Diagnosis to Therapy. , 2016, Hypertension.

[18]  P. Newman,et al.  Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31) , 2016, Current opinion in hematology.

[19]  A. Khvorova,et al.  A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo. , 2016, Nucleic acid therapeutics.

[20]  P. Kussie,et al.  Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension , 2016, Hypertension.

[21]  T. Benzing,et al.  Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. , 2016, Journal of the American Society of Nephrology : JASN.

[22]  S. Brennecke,et al.  Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.

[23]  B. Burington,et al.  Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis. , 2015, The New England journal of medicine.

[24]  A. Shub,et al.  Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity , 2015, Hypertension.

[25]  A. Khvorova,et al.  Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain , 2015, Molecular therapy. Nucleic acids.

[26]  Hong Cao,et al.  Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs , 2015, Nucleic acids research.

[27]  M. McDevitt,et al.  Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. , 2015, The New England journal of medicine.

[28]  C. Bennett,et al.  Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. , 2015, Advanced drug delivery reviews.

[29]  Colby A. Souders,et al.  Circulating Levels of sFlt1 Splice Variants as Predictive Markers for the Development of Preeclampsia , 2015, International journal of molecular sciences.

[30]  S. Milstein,et al.  siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. , 2015, ACS chemical biology.

[31]  Amy Chan,et al.  Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.

[32]  S. Gambhir,et al.  Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. , 2014, The Journal of clinical investigation.

[33]  R. Romero,et al.  Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study , 2014, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[34]  S. Kaushal,et al.  Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[35]  Jing Liu,et al.  Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression , 2012, Cell.

[36]  K. Lim,et al.  Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia , 2012, Circulation.

[37]  S. Karumanchi,et al.  Hemodynamic, Vascular, and Reproductive Impact of FMS-Like Tyrosine Kinase 1 (FLT1) Blockade on the Uteroplacental Circulation During Normal Mouse Pregnancy1 , 2012, Biology of reproduction.

[38]  S. Karumanchi,et al.  Transcriptionally Active Syncytial Aggregates in the Maternal Circulation May Contribute to Circulating Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia , 2012, Hypertension.

[39]  L. Cartegni,et al.  Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. , 2011, Molecular cell.

[40]  Santosh A. Khedkar,et al.  Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia , 2011, Circulation.

[41]  D. Schust,et al.  Preeclampsia: Animal models for a human cure , 2011, Proceedings of the National Academy of Sciences.

[42]  R. Levine,et al.  Pathogenesis of preeclampsia. , 2010, Annual review of pathology.

[43]  A. Gruber,et al.  Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model , 2009, Journal of cellular and molecular medicine.

[44]  L. Florea,et al.  Novel splice variants of sFlt1 are upregulated in preeclampsia. , 2009, Placenta.

[45]  S. Yagel,et al.  A Novel Human-Specific Soluble Vascular Endothelial Growth Factor Receptor 1: Cell Type-Specific Splicing and Implications to Vascular Endothelial Growth Factor Homeostasis and Preeclampsia , 2008, Circulation research.

[46]  Anastasia Khvorova,et al.  Experimental validation of the importance of seed complement frequency to siRNA specificity. , 2008, RNA.

[47]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[48]  A. Reynolds,et al.  A protocol for designing siRNAs with high functionality and specificity , 2007, Nature Protocols.

[49]  P. McKenzie,et al.  Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. , 2007, Kidney international.

[50]  G. Saade,et al.  The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. , 2007, American journal of obstetrics and gynecology.

[51]  James H Brown,et al.  Scaling of number, size, and metabolic rate of cells with body size in mammals , 2007, Proceedings of the National Academy of Sciences.

[52]  R. Yu,et al.  Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100 , 2007, Drug Metabolism and Disposition.

[53]  J. Martin Collinson,et al.  Corneal avascularity is due to soluble VEGF receptor-1 , 2006, Nature.

[54]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[55]  R. Romero,et al.  Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[56]  I. Sargent,et al.  Latest Advances in Understanding Preeclampsia , 2005, Science.

[57]  R. Griffey,et al.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. , 2005, Journal of medicinal chemistry.

[58]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[59]  Asif Ahmed,et al.  Elevated Placental Soluble Vascular Endothelial Growth Factor Receptor-1 Inhibits Angiogenesis in Preeclampsia , 2004, Circulation research.

[60]  R. Romero,et al.  Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. , 2004, American journal of obstetrics and gynecology.

[61]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[62]  T. Du,et al.  Asymmetry in the Assembly of the RNAi Enzyme Complex , 2003, Cell.

[63]  S. Jayasena,et al.  Functional siRNAs and miRNAs Exhibit Strand Bias , 2003, Cell.

[64]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[65]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[66]  E. Thornton.  Diagnosis is Therapy , 1980 .

[67]  S. Govoni,et al.  Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development. , 2016, Pharmacological research.

[68]  B. Dogdas,et al.  Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth. , 2016 .

[69]  A. Khvorova,et al.  Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain. , 2016, Molecular therapy. Nucleic acids.

[70]  B. Sibai,et al.  Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. , 2010, American journal of obstetrics and gynecology.

[71]  A. Jeyabalan,et al.  Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. , 2009, Placenta.

[72]  Q. Boese,et al.  Identifying siRNA-induced off-targets by microarray analysis. , 2008, Methods in molecular biology.

[73]  J. Manson,et al.  Prospective Study of , 2007 .